Beloved friends and supporters

United States, 16th Jan 2024, King NewsWire – I’m a U.S. Army veteran and a survivor of Triple Negative Breast Cancer (TNBC). Diagnosed in August 2021, my journey has been one of resilience and determination. I underwent a rigorous treatment plan, enduring 5 months of intravenous chemotherapy with immunotherapy, followed by a lumpectomy in March 2022, and 30 radiation sessions in June 2022. Encouragingly, my scans in August 2022 were positive, prompting the addition of Xeloda to eliminate any residual cancer cells. I successfully completed the Xeloda treatments in February 2023.

Despite these efforts, a recent November 2023 mammogram revealed small calcifications near the surgical bed, indicating a breast cancer recurrence. To combat this setback, I am now exploring alternative treatments both within and outside the U.S. One promising option is Dendritic Cell Therapy, a groundbreaking approach in Europe.

Dendritic Cell Therapy involves utilising dendritic cells and a patient’s blood sample, combining them in a lab. After a week of incubation, the reinvigorated dendritic cells are reintroduced into the body, acting as a personalised vaccine to combat and reduce cancer recurrences.

As I embark on this new phase of treatment, I am reaching out to seek your support in making Dendritic Cell Therapy and other complementary treatments possible. Your contribution will play a crucial role in enhancing my chances of overcoming this recurrence and achieving a healthier future.

Join me in this fight against cancer, and together, let’s make a difference.

Thanks for your support.
Yasmin Schlegel

For media inquiries, please contact:

Yasmin Schlegel
703-474-4066
yasmin.schlegel@gmail.com
http://spot.fund/s9wrwsc

Media Contact

Organization: Spotfund.

Contact Person: YASMIN SCHLEGEL

Website: http://spot.fund/s9wrwsc

Email: Send Email

Country: United States

Release Id: 1601248921

The post Join Yasmin Schlegel’s Journey Against Breast Cancer Recurrence appeared first on King NewsWire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.